Perspective Therapeutics Q3 net loss widens to $26 mln

Reuters11-11

<a href="https://laohu8.com/S/CATX">Perspective Therapeutics</a> Q3 net loss widens to $26 mln

Overview

Perspective Therapeutics Q3 net loss widens to $26 mln, EPS at -$0.35
Research and development expenses rose 69% yr/yr in Q3 2025
Cash reserves of $174 mln expected to fund operations into late 2026

Outlook

Company expects funding to support operations into late 2026

Result Drivers

R&D EXPENSES - R&D expenses increased 69% in Q3 2025, driven by higher clinical site activities and personnel costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Grant Revenue		$209,000
Q3 EPS		-$0.35
Q3 Net Income		-$25.97 mln
Q3 Net Income from Cont Ops		-$25.97 mln
Q3 Operating Income		-$27.86 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Perspective Therapeutics Inc is $13.50, about 83.7% above its November 7 closing price of $2.20

Press Release: ID:nGNX1R0LP5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582388928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582388928","market":"fut","top_or_hot":-1,"title":"Perspective Therapeutics Q3 net loss widens to $26 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> Q3 net loss widens to $26 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Perspective <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens to $26 mln, EPS at -$0.35</p></li><li><p>Research and development expenses rose 69% yr/yr in Q3 2025</p></li><li><p>Cash reserves of $174 mln expected to fund operations into late 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects funding to support operations into late 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - R&amp;D expenses increased 69% in Q3 2025, driven by higher clinical site activities and personnel costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Grant Revenue</p></td><td></td><td><p>$209,000</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$25.97 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income from Cont Ops</p></td><td></td><td><p>-$25.97 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$27.86 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Perspective Therapeutics Inc is $13.50, about 83.7% above its November 7 closing price of $2.20</p></li></ul><p>Press Release: <span>ID:nGNX1R0LP5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Perspective Therapeutics Q3 net loss widens to $26 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPerspective Therapeutics Q3 net loss widens to $26 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> Q3 net loss widens to $26 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Perspective <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens to $26 mln, EPS at -$0.35</p></li><li><p>Research and development expenses rose 69% yr/yr in Q3 2025</p></li><li><p>Cash reserves of $174 mln expected to fund operations into late 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects funding to support operations into late 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - R&amp;D expenses increased 69% in Q3 2025, driven by higher clinical site activities and personnel costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Grant Revenue</p></td><td></td><td><p>$209,000</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$25.97 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income from Cont Ops</p></td><td></td><td><p>-$25.97 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$27.86 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Perspective Therapeutics Inc is $13.50, about 83.7% above its November 7 closing price of $2.20</p></li></ul><p>Press Release: <span>ID:nGNX1R0LP5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM125:1","article_id":"2582388928","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582388928","pubTimestamp":1762809808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Perspective Therapeutics Q3 net loss widens to $26 mlnOverviewPerspective Therapeutics Q3 net loss widens to $26 mln, EPS at -$0.35Research and development expenses rose 69% yr/yr in Q3 2025Cash reser","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CATX":"Perspective Therapeutics"},"translate_title":"Perspective Therapeutics第三季度净亏损扩大至2600万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CATX":0.9},"content_text":"Perspective Therapeutics Q3 net loss widens to $26 mlnOverviewPerspective Therapeutics Q3 net loss widens to $26 mln, EPS at -$0.35Research and development expenses rose 69% yr/yr in Q3 2025Cash reserves of $174 mln expected to fund operations into late 2026OutlookCompany expects funding to support operations into late 2026Result DriversR&D EXPENSES - R&D expenses increased 69% in Q3 2025, driven by higher clinical site activities and personnel costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Grant Revenue$209,000Q3 EPS-$0.35Q3 Net Income-$25.97 mlnQ3 Net Income from Cont Ops-$25.97 mlnQ3 Operating Income-$27.86 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Perspective Therapeutics Inc is $13.50, about 83.7% above its November 7 closing price of $2.20Press Release: ID:nGNX1R0LP5For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582388928","isCrawlerRequest":true}